Comment on IPO-bound Aduro snags Big Pharma cancer immunotherapy deal

IPO-bound Aduro snags Big Pharma cancer immunotherapy deal

Tiny Aduro Biotech Inc. hopes to put the STING on cancer with a potential $750 million deal between the Berkeley company and drug giant Novartis AG. The deal centers on experimental synthetic small molecules, developed by Aduro, that could be the latest weapon in the hot field of cancer immunotherapy. The molecules bind to a receptor for a protein known as STING, which researchers believe plays a critical role in helping the immune system recognize and marshal its tumor-fighting forces against cancer. What's…

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News